Literature DB >> 8577927

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

K Hupe-Sodmann1, G P McGregor, R Bridenbaugh, R Göke, B Göke, H Thole, B Zimmermann, K Voigt.   

Abstract

The post-secretory processing of the potent insulinotropic peptide hormone, GLP-1(7-36)amide, probably involves one or more of a small group of membrane-bound ectopeptidases. Reported here, is the characterisation of the endoproteolysis of human GLP-1(7-36)amide by the recombinant human form of neutral endopeptidase (NEP) 24.11, which is one of the best characterised and widely-distributed of ectopeptidases and is involved in the processing of other peptide hormones. The products of the limited endoproteolysis were characterised by mass and primary structure following fractionation using high performance liquid chromatography. The rate of this endoproteolysis by NEP 24.11 was estimated and compared to that of GLP-1(7-36)amide-related peptides. GLP-1(7-36)amide appears to be good substrate for NEP 24.11 with most, but not all potential target bonds being cleaved. Also, the structurally-related peptides, secretin and glucagon appear to be good substrates whereas GIP and exendin-4 are very poor substrates. That the GLP-1(7-36)amide super-agonist, exendin-4 is a poor substrate for NEP 24.11 is significant for the possible use of this peptide as a prototype for the development of clinically-useful peptide agonists. Further studies should reveal whether NEP 24.11 is important for the metabolic clearance of GLP-1(7-36)amide and will be highly relevant for the attempts to realise the suggested therapeutic value of GLP-1(7-36)amide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8577927     DOI: 10.1016/0167-0115(95)00063-h

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  61 in total

1.  Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

Authors:  Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  Does GLP-1 suppress its own basal secretion?

Authors:  Dariush Elahi; Dennis A Ruff; Olga D Carlson; Graydon S Meneilly; Joel F Habener; Josephine M Egan
Journal:  Endocr Res       Date:  2015-07-17       Impact factor: 1.720

3.  Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.

Authors:  Irina Velikyan; Thomas N Bulenga; Ramkumar Selvaraju; Mark Lubberink; Daniel Espes; Ulrika Rosenström; Olof Eriksson
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

4.  Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.

Authors:  Miriam Amiram; Kelli M Luginbuhl; Xinghai Li; Mark N Feinglos; Ashutosh Chilkoti
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.

Authors:  Jacqueline H Parilla; Rebecca L Hull; Sakeneh Zraika
Journal:  J Histochem Cytochem       Date:  2018-03-19       Impact factor: 2.479

7.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

8.  GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs.

Authors:  Dariush Elahi; Franca S Angeli; Amin Vakilipour; Olga D Carlson; Eva Tomas; Josephine M Egan; Joel F Habener; Richard P Shannon
Journal:  Peptides       Date:  2014-06-14       Impact factor: 3.750

9.  Role and development of GLP-1 receptor agonists in the management of diabetes.

Authors:  Chee W Chia; Josephine M Egan
Journal:  Diabetes Metab Syndr Obes       Date:  2009-05-15       Impact factor: 3.168

10.  Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.

Authors:  Kwang-Chul Kwon; Ramya Nityanandam; James S New; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2012-10-18       Impact factor: 9.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.